5 Undervalued Oncology Stocks Wall Street Is Overlooking

Oncology spending is projected to reach $441 billion by 2029, but market growth is expected to slow as established therapies face generic and biosimilar competition. Several oncology blockbusters are also approaching loss of exclusivity, including Pfizer's Ibrance in 2027–2028 and Bristol Myers Squibb's Opdivo in 2028–2030. Overall, the oncology rally has been broad, but I believe several underappreciated companies still offer meaningful upside.

Seeking Alpha • 10 hours ago

Does Fidelity or iShares Have the Better Healthcare ETF For Investors Seeking Broad Exposure?

Fidelity MSCI Health Care Index ETF has a significantly lower expense ratio than iShares Global Healthcare ETF. iShares Global Healthcare ETF provides exposure to international healthcare markets, whereas the Fidelity fund focuses on U.S. equities.

The Motley Fool • Sep 16, 2026

Should You Invest in the Fidelity MSCI Health Care Index ETF (FHLC)?

Designed to provide broad exposure to the Healthcare - Broad segment of the equity market, the Fidelity MSCI Health Care Index ETF (FHLC) is a passively managed exchange traded fund launched on October 21, 2013.

Zacks Investment Research • Sep 15, 2026

Tackle Market Uncertainty With Strategic Healthcare Exposure

With much of the attention in the capital markets directed towards the technology sector, it's easy to forget other sectors like healthcare. However, it's key to consider other sectors within your portfolio to help hedge against heavy volatility.

ETF Trends • Sep 14, 2026

Which Healthcare ETF Is the Better Buy: Fidelity's Broad FHLC or State Street's Pharma-Focused XPH?

Fidelity MSCI Health Care Index ETF offers a lower expense ratio of 0.08% compared to the 0.35% charged by State Street SPDR S&P Pharmaceuticals ETF. State Street SPDR S&P Pharmaceuticals ETF focuses specifically on the pharmaceutical industry, whereas Fidelity MSCI Health Care Index ETF tracks the broader healthcare sector.

The Motley Fool • Sep 10, 2026

Health Care's Next Act: Tailwinds Emerging Across R&D Cycle

Pharmaceuticals are rebounding as U.S. drug pricing clarity emerges, shifting focus to patent expirations and innovation-driven differentiation. Companies like JNJ and AZN, with diversified portfolios and strong R&D pipelines, are better positioned to offset looming patent cliffs.

Seeking Alpha • Sep 8, 2026

Healthcare ETF Comparison: Fidelity's FHLC vs. Invesco's Biotech-Focused IBBQ

The Fidelity MSCI Health Care Index ETF features a lower expense ratio of 0.08% and a higher dividend yield of 1.2%. The Invesco Nasdaq Biotechnology ETF has delivered a higher 1-year total return of 56.4% but carries a more significant maximum drawdown of 37.9%.

The Motley Fool • Sep 2, 2026

Big Pharma's Comeback Is Here: Winners, Losers, And 4 ETFs

Nine of the 16 Big Pharma stocks covered in this article set new 52-week highs during August, reflecting strong momentum across the sector. Also, the rally has been driven by strong Q2 results, as well as Wall Street's growing shift toward healthcare amid continued geopolitical tensions in the Middle East.

Seeking Alpha • Aug 31, 2026

FHLC vs. PJP: Which Healthcare ETF Is the Better Buy for Investors?

Fidelity MSCI Health Care Index ETF (FHLC) offers a significantly lower expense ratio and a higher dividend yield than the Invesco Pharmaceuticals ETF (PJP). PJP provides a concentrated portfolio of just over 30 pharmaceutical stocks, while FHLC diversifies across more than 300 holdings.

The Motley Fool • Aug 23, 2026

Health Care Shakes Off A 5-Day Slide

Health Care ended a five-day losing streak on Wednesday with a 1.34% rally. The streak tied the five days ending June 18 for the sector's longest of 2026.

Seeking Alpha • Aug 7, 2026